ProCE Banner Activity

Phase Ib Study of Sabatolimab + Hypomethylating Agents for Very High–Risk/High-Risk MDS and Newly Diagnosed AML: Final Analysis

Slideset Download
Conference Coverage
In patients with high-risk or very high–risk MDS or newly diagnosed AML, sabatolimab in combination with HMA was generally well tolerated with durable efficacy.

Released: December 14, 2021

Expiration: December 13, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation